Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...
Eagle-Tribune6d
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for ...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...
Medscape23d
Should Patients with Abnormal Liver Function Tests in Primary Care be Tested for Chronic Viral Hepatitis
Primary biliary cirrhosis (PBC) 0.024 [49] Antimitochondrial Ab Raised antibodies and raised ALP level. Autoimmune hepatitis 0.001 [50] Smooth Muscle Ab Raised antibodies and raised ALT ...
The Motley Fool24d
Is AST SpaceMobile Stock a Buy?
AST SpaceMobile announced partnerships with AT&T and Verizon this year. On Sept. 12, it launched the first five of its BlueBird satellites into low Earth orbit. Its space mobile service has yet to ...
Seeking Alpha27d
AST SpaceMobile: Bulls Are In Control With New Highs Possible
To say that AST SpaceMobile (NASDAQ:ASTS) has had an interesting year would be putting it mildly. The company that is seeking to be an early mover in satellite broadband phone/data services has ...
Yahoo Finance27d
Jim Cramer Says AST Spacemobile (NASDAQ:ASTS) is ‘Too Hot’
We recently published a list of Jim Cramer October Portfolio: Top 10 Stocks to Buy and Sell.Since AST SpaceMobile Inc (NASDAQ:ASTS) ranks 9th on the list, it deserves a deeper look. Jim Cramer in ...